NCT05051436View on ClinicalTrials.gov

The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics

PHASE4RecruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

December 13, 2021

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Pre-diabetesObesity
Interventions
DRUG

Mirabegron 50 MG

Mirabegron 50 mg/day will be administered for 14 weeks.

DRUG

Tadalafil 10 MG

Tadalafil 10 mg/day will be administered for 14 weeks after baseline procedures.

DRUG

Placebo

Placebo will be administered for 14 weeks after baseline procedures.

Trial Locations (1)

40536

RECRUITING

University of Kentucky, Lexington

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Philip Kern

OTHER